Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users : Imaging With the Novel Radiotracer [ 11 C ] CURB
暂无分享,去创建一个
Alan A. Wilson | S. Houle | S. Kish | R. Tyndale | I. Boileau | R. Mizrahi | M. Huestis | P. Rusjan | D. Payer | J. Tong | B. Foll | Belinda Williams | E. Mansouri
[1] A. Hariri,et al. Interactions Between Anandamide and Corticotropin-Releasing Factor Signaling Modulate Human Amygdala Function and Risk for Anxiety Disorders: An Imaging Genetics Strategy for Modeling Molecular Interactions , 2016, Biological Psychiatry.
[2] J. Deussing,et al. Sustained glucocorticoid exposure recruits cortico-limbic CRH signaling to modulate endocannabinoid function , 2016, Psychoneuroendocrinology.
[3] R. Spanagel,et al. Enhanced Functional Activity of the Cannabinoid Type-1 Receptor Mediates Adolescent Behavior , 2015, The Journal of Neuroscience.
[4] Alan A. Wilson,et al. Blocking of Fatty Acid Amide Hydrolase Activity with PF-04457845 in Human Brain: A Positron Emission Tomography Study with the Novel Radioligand [11C]CURB , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[5] Alan A. Wilson,et al. The Fatty Acid Amide Hydrolase C385A Variant Affects Brain Binding of the Positron Emission Tomography Tracer [11C]CURB , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[6] S. Dey,et al. Endocannabinoid signaling at the periphery: 50 years after THC. , 2015, Trends in pharmacological sciences.
[7] J. Wieser,et al. Poorer frontolimbic white matter integrity is associated with chronic cannabis use, FAAH genotype, and increased depressive and apathy symptoms in adolescents and young adults , 2015, NeuroImage: Clinical.
[8] J. Os,et al. [18F]MK‐9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users , 2015, Addiction biology.
[9] Andrew T. Drysdale,et al. FAAH genetic variation enhances fronto-amygdala function in mouse and human , 2015, Nature Communications.
[10] D. Deutsch,et al. Fatty Acid-binding Proteins (FABPs) Are Intracellular Carriers for Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)* , 2015, The Journal of Biological Chemistry.
[11] S. Pasquaré,et al. Normal aging in rats and pathological aging in human Alzheimer’s disease decrease FAAH activity: Modulation by cannabinoid agonists , 2014, Experimental Gerontology.
[12] Alan A. Wilson,et al. Whole-Body Radiation Dosimetry of 11C-Carbonyl-URB694: A PET Tracer for Fatty Acid Amide Hydrolase , 2014, The Journal of Nuclear Medicine.
[13] B. Crespo-Facorro,et al. Immune system: A possible nexus between cannabinoids and psychosis , 2014, Brain, Behavior, and Immunity.
[14] Nathalie A. Desrosiers,et al. Urinary cannabinoid disposition in occasional and frequent smokers: is THC-glucuronide in sequential urine samples a marker of recent use in frequent smokers? , 2014, Clinical chemistry.
[15] D. Piomelli. More surprises lying ahead. The endocannabinoids keep us guessing , 2014, Neuropharmacology.
[16] L. C. Bidwell,et al. Impulsivity, variation in the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes, and marijuana-related problems. , 2013, Journal of studies on alcohol and drugs.
[17] C. Kahler,et al. Working memory and impulsivity predict marijuana-related problems among frequent users. , 2013, Drug and alcohol dependence.
[18] J. Hirvonen,et al. Population-Based Input Function Modeling for [18F]FMPEP-d 2, an Inverse Agonist Radioligand for Cannabinoid CB1 Receptors: Validation in Clinical Studies , 2013, PloS one.
[19] L. Panlilio,et al. Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction. , 2013, Pharmacology & therapeutics.
[20] B. Brandner,et al. Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms , 2013, British Journal of Psychiatry.
[21] J. Hirvonen,et al. Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws. , 2013, Clinical chemistry.
[22] Sylvain Houle,et al. Mapping Human Brain Fatty Acid Amide Hydrolase Activity with PET , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[23] W. M. Bosker,et al. Psychomotor Function in Chronic Daily Cannabis Smokers during Sustained Abstinence , 2013, PloS one.
[24] A. Shukla,et al. Susceptibility of the adolescent brain to cannabinoids: long-term hippocampal effects and relevance to schizophrenia , 2012, Translational Psychiatry.
[25] T. Smart,et al. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee , 2012, PAIN®.
[26] Garth E. Terry,et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers , 2012, Molecular Psychiatry.
[27] G. Jay,et al. Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects. , 2012, British journal of clinical pharmacology.
[28] M. Huestis,et al. Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. , 2011, Clinical chemistry.
[29] T. Bisogno,et al. Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes , 2011, British journal of pharmacology.
[30] M. Huestis,et al. Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography–tandem mass spectrometry , 2011, Analytical and bioanalytical chemistry.
[31] Benjamin F. Cravatt,et al. Mechanistic and Pharmacological Characterization of PF-04457845: A Highly Potent and Selective Fatty Acid Amide Hydrolase Inhibitor That Reduces Inflammatory and Noninflammatory Pain , 2011, Journal of Pharmacology and Experimental Therapeutics.
[32] A. Krishna,et al. Effects of chronic bhang (cannabis) administration on the reproductive system of male mice. , 2011, Birth defects research. Part B, Developmental and reproductive toxicology.
[33] Shobha N. Bhattachar,et al. Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. , 2011, ACS medicinal chemistry letters.
[34] M. Nagarkatti,et al. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. , 2010, Immunobiology.
[35] Ursula S. Myers,et al. Individual and Additive Effects of the CNR1 and FAAH Genes on Brain Response to Marijuana Cues , 2010, Neuropsychopharmacology.
[36] R. Mangieri,et al. The endocannabinoid system as a target for the treatment of cannabis dependence , 2009, Neuropharmacology.
[37] R. Herning,et al. Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? , 2009, Addiction.
[38] R. Herning,et al. Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. , 2009, Drug and alcohol dependence.
[39] S. Glaser,et al. Temporal changes in mouse brain fatty acid amide hydrolase activity , 2009, Neuroscience.
[40] R. Herning,et al. Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers. , 2009, Journal of analytical toxicology.
[41] S. Heishman,et al. Reliability and validity of a short form of the Marijuana Craving Questionnaire. , 2009, Drug and alcohol dependence.
[42] Joseph P. Schacht,et al. Intermediate cannabis dependence phenotypes and the FAAH C385A variant: an exploratory analysis , 2009, Psychopharmacology.
[43] M. Seierstad,et al. Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. , 2008, Journal of medicinal chemistry.
[44] Kent E Hutchison,et al. Marijuana withdrawal and craving: influence of the cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes. , 2008, Addiction.
[45] M. Huestis,et al. Marijuana Neurobiology and Treatment , 2008, Substance abuse.
[46] M. Maftouh,et al. CB1 receptor‐mediated control of the release of endocannabinoids (as assessed by microdialysis coupled with LC/MS) in the rat hypothalamus , 2007, The European journal of neuroscience.
[47] M. Pistis,et al. Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2. , 2007, European journal of pharmacology.
[48] M. Hellmich,et al. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use , 2007, Schizophrenia Research.
[49] R. Tyndale,et al. The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: Studies of drug use and dependence in caucasians , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[50] J. Whitaker,et al. Inhibition of microglial fatty acid amide hydrolase modulates LPS stimulated release of inflammatory mediators , 2007, FEBS letters.
[51] E. Cudaback,et al. Identification of a Novel Endocannabinoid-Hydrolyzing Enzyme Expressed by Microglial Cells , 2007, The Journal of Neuroscience.
[52] J. Villares. Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain , 2007, Neuroscience.
[53] D. Selley,et al. Prolonged Recovery Rate of CB1 Receptor Adaptation after Cessation of Long-Term Cannabinoid Administration , 2006, Molecular Pharmacology.
[54] Shitij Kapur,et al. An automated method for the extraction of regional data from PET images , 2006, Psychiatry Research: Neuroimaging.
[55] Daniele Piomelli,et al. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). , 2006, CNS drug reviews.
[56] T. Hauet,et al. THC can be detected in brain while absent in blood. , 2005, Journal of analytical toxicology.
[57] M. Cebeira,et al. Cannabinoid tolerance and dependence: A review of studies in laboratory animals , 2005, Pharmacology Biochemistry and Behavior.
[58] B. Cravatt,et al. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. , 2004, Human molecular genetics.
[59] M. Cascio,et al. Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence. , 2004, Drug and alcohol dependence.
[60] M. Eid,et al. Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students , 2004, Human & experimental toxicology.
[61] B. Cravatt,et al. A missense mutation in human fatty acid amide hydrolase associated with problem drug use , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[62] B. Cravatt,et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[63] T. Bisogno,et al. Enhancement of Anandamide Formation in the Limbic Forebrain and Reduction of Endocannabinoid Contents in the Striatum of Δ9‐Tetrahydrocannabinol‐Tolerant Rats , 2000, Journal of neurochemistry.
[64] J. Hughes,et al. Marijuana withdrawal among adults seeking treatment for marijuana dependence. , 1999, Addiction.
[65] Stephen P. Mayfield,et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides , 1996, Nature.
[66] J. Schwartz,et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons , 1994, Nature.
[67] D. Deutsch,et al. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. , 1993, Biochemical pharmacology.
[68] M. Herkenham,et al. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study , 1993, Brain Research.
[69] L. Sobell,et al. Validity of alcoholic's self-reports: duration data. , 1981, The International journal of the addictions.
[70] R. Mechoulam,et al. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish , 1964 .
[71] C. Fowler. The Potential of Inhibitors of Endocannabinoid Metabolism for Drug Development: A Critical Review. , 2015, Handbook of experimental pharmacology.
[72] W. Hall. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? , 2015, Addiction.
[73] J. Rehm,et al. Gender differences in prevalence of substance use disorders among individuals with lifetime exposure to substances: results from a large representative sample. , 2013, The American journal on addictions.